Need a certification?
We want you to feel confident that you're receiving the best training, so Anaphylaxis Awareness Level 2 (VTQ) is fully available for preview below. If you're in need of a certificate of completion for work, create your account today to track your progress.
Peanut allergies are becoming more and more common in children, and this usually continues into adulthood. In severe cases, a peanut allergy can be life threatening, and at this moment in time there is no approved treatment for it. A current study is investigating a new drug and its effectiveness to reduce the symptoms seen in people with severe peanut allergies. The new drug being tested is called AR101 and it’s based on peanut protein, with the idea being that the dose is gradually increased to build up tolerance. This treatment is not a cure to peanut allergies, rather its aim is to make people with severe allergies less likely to experience a serious reaction if they are exposed to peanuts. This drug is not available in all countries but it has been licensed in the USA by the Food and Drug Administration or FDA, as an approved drug in the reduction of allergic reaction incidence and severity in patients aged 4-17 years old with a peanut allergy. The trial involved a total of 555 participants, 499 children and 56 adults, and was carried out in 10 countries in North America and Europe. The study compared the drug AR101 with a dummy powder, a placebo. Some participants received the real drug, which was gradually increased over a 12 month period. The other participants received the placebo, which was also gradually increased over 12 months. It is important to note that all tolerance tests were conducted in a research facility under medical supervision. This meant that participants could receive immediate medical attention if they experienced a severe allergic reaction. So, what were the results? Well, the research showed that young people with peanut allergies could experience a reduction in the severity of their symptoms, and a greater ability to tolerate small amounts of peanut protein following treatment with AR101 compared with the placebo. The study also showed that although this treatment appeared to work in children and adolescents, it had no significant effect in adults. The reason behind this has not yet been made clear. There are continuous ongoing studies for peanut allergies in the attempt to offer some hope for parents and children with serious peanut allergies. We must point out that tolerance testing should never be attempted at home. Allergic reactions can be life threatening if not treated immediately.
New Hope for Peanut Allergies: AR101 Drug Study
Rising Prevalence of Peanut Allergies
Childhood to Adulthood:
Peanut allergies are on the rise, affecting children and often persisting into adulthood. Severe cases can be life-threatening.
The AR101 Drug Study
Exploring AR101:
A groundbreaking study is underway to assess the effectiveness of the AR101 drug in mitigating symptoms of severe peanut allergies.
Building Tolerance Gradually
How AR101 Works:
AR101, a peanut protein-based drug, gradually increases the dose to build tolerance. It doesn't cure peanut allergies but aims to reduce the risk of severe reactions upon peanut exposure.
US FDA Approval
Licensed Treatment:
AR101 has gained approval from the US Food and Drug Administration (FDA) for reducing allergic reaction incidence and severity in patients aged 4-17 with peanut allergies.
International Research
Extensive Trial:
The study involved 555 participants, including 499 children and 56 adults, across 10 countries in North America and Europe. AR101 was compared to a placebo, with both groups undergoing gradual increases over a year.
Supervised Tolerance Testing
Safe Clinical Environment:
During the trial, all tolerance tests were conducted under medical supervision in research facilities, ensuring immediate medical attention for severe allergic reactions.
Positive Findings in Youth
Reduced Severity and Improved Tolerance:
Results indicate that young individuals with peanut allergies experienced a decrease in symptom severity and an enhanced ability to tolerate small amounts of peanut protein with AR101 treatment compared to the placebo. However, the drug did not significantly impact adults, with the reason still under investigation.
Continued Research for Hope
Promising Future:
Ongoing studies are dedicated to finding solutions for serious peanut allergies, offering hope to affected individuals and their families. It's crucial to highlight that tolerance testing should never be attempted at home due to the life-threatening nature of allergic reactions.